Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Biotechnology

Healthcare
$8.04 +1.97%

+$0.15 today

Market cap
$231.73M
Beta
2.35
P/E (TTM)
-2.7
EPS (TTM)
-$2.77
52W Low $5.85High $24.17

Volume 0.64M

Average 0.43M

ARCT Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $658K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $4M.

Context

  • Cost of revenue amounted to 4.5% of revenue in FY2025, up 4.5 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $658K or moves back toward the trailing-twelve-month quarterly average of $1M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$658K— QoQ
Last fiscal yearDec 2025
$3.03M— YoY
LTMMar 2026
$4M— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
3.03M USD
Year-over-year change
—

Cost of Revenue vs competitors

How ARCT compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Cost of revenue amounts to 8.8% of revenue for ARCT, versus a peer median of 24.5%.
ARCT Competitors
Cost of Revenue for ARCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VALNValneva SELTM Mar 2026€110.28M EUR+10.9%-30.9%70.5%
NVAXNovavax, Inc.LTM Mar 2026$91.62M USD-41.9%-57.1%15.4%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$40.76M USD+72.9%——
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$4M USD——8.8%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$2.24M USD+39.7%——
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$2.15M USD-8.3%——
PRQRProQR Therapeutics N.V.LTM Mar 2026€1.38M EUR——10.3%
SLNSilence Therapeutics plcLTM Mar 2026$309.37K USD—-73.0%33.6%
BNTCBenitec Biopharma Inc.LTM Mar 2026$119K USD-36.4%——
ABUSArbutus Biopharma CorporationLTM Mar 2026$33K USD-99.8%—0.0%
VIRVir Biotechnology, Inc.LTM Mar 2026-$114.78M USD-122.6%-73.4%175.2%
Peer median (excluding ARCT) —-22.3%-65.1%24.5%

Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.36M205.76M157.75M138.39M67.22M
Cost of Revenue00003.03M
Gross Profit12.36M205.76M157.75M138.39M64.2M
Gross Margin100.0%100.0%100.0%100.0%95.5%
Research & Development173.76M147.75M192.13M195.16M112.21M
Selling, General & Admin41.45M46.07M52.87M52.82M46.08M
Operating Expenses215.21M193.58M235.95M234.06M139.15M
Depreciation & Amortization1.19M1.53M2.96M3.54M3.03M
EBITDA(199.81M)15.17M(24.17M)(77.4M)(62.76M)
EBITDA Margin-1616.7%7.4%-15.3%-55.9%-93.4%
Operating Income(202.85M)12.18M(78.21M)(95.67M)(74.96M)
Operating Margin-1641.3%5.9%-49.6%-69.1%-111.5%
Interest Income753K2.58M17.36M15.2M10.1M
Interest Expense2.67M3M767K00
Other Income / Expenses(822K)(1.53M)50.32M14.72M9.17M
Income Before Tax(203.67M)10.64M(27.89M)(80.95M)(65.78M)
Pre-Tax Margin-1648.0%5.2%-17.7%-58.5%-97.9%
Income Tax Expense01.3M1.84M(4K)0
Net Income(203.67M)9.35M(29.73M)(80.94M)(65.78M)
Net Margin-1648.0%4.5%-18.8%-58.5%-97.9%
EPS (Basic)(7.74)0.35(1.12)(3.00)(2.40)
EPS (Diluted)(7.74)0.35(1.12)(3.00)(2.40)
Weighted Avg Shares26.32M26.45M26.63M27M27.39M
Weighted Avg Shares (Diluted)26.32M27.09M26.63M27M27.39M

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Intrinsic Alpha fair value

Locked

Current Price

$8.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.